Catalyst Dossier · compiled by CeliA 🧫

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVJF)

Biotechnology · market cap $52.1B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-09-15 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Teva Pharmaceutical Industries (TEVJF) is a large-cap global pharmaceutical company with 31,173 employees and a market cap of approximately $52 billion. The company operates across branded and generic pharmaceuticals, with a deep late-stage pipeline spanning neurology, respiratory, and oncology indications. Key late-stage assets include ACR16 (Phase 3, Huntington's Disease), TEV-50717 (Phase 3, Tourette Syndrome), TV-46000 (Phase 3, Schizophrenia), Fremanezumab (Phase 3, Migraine), and multiple respiratory programs.

The catalyst path

2026-09-15 (est.)Phase 2 · TEV-53408imp 7/10

Pipeline

Asset	Phase	Indication
ACR16	Phase 3	Huntington's Disease
FS MDPI	Phase 3	Asthma
TEV-50717	Phase 3	Tourette Syndrome
Albuterol MDPI	Phase 3	Asthma
TV-46000	Phase 3	Schizophrenia
Omacetaxine mepesuccinate	Phase 2	Chronic Myeloid Leukemia
TP-38	Phase 2	Glioblastoma Multiforme
Fp MDPI	Phase 2	Asthma
Talampanel	Phase 2	Epilepsy
Hydrocodone ER	Phase 3	Chronic Pain
Rasagiline Mesylate	Phase 3	Parkinson's Disease
TEV-56286	Phase 2	Multiple System Atrophy
Fremanezumab	Phase 3	Migraine
Laquinimod	Phase 3	Lupus Arthritis
Reslizumab	Phase 3	Eosinophilic Asthma
TV-45070	Phase 2	Osteoarthritis of the Knee
Glatiramer Acetate	Phase 3	Optic Neuritis
Beclomethasone dipropionate	Phase 3	Rhinitis, Allergic, Perennial

Price & technical context

3-month

+99.8%

6-month

+60.7%

12-month

+63.5%

52-wk range

$13.73–$28.61

vs 50-day MA

+29.4%

vs 200-day MA

+65.2%

Realized vol

72.5%

Max drawdown

-39.6%

Daily closes through 2025-12-11. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for TEVJF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.